GW 0742
Characteristics
- Chemical Name: [4-[[[2-[3-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2-methylphenoxy]acetic acid
- Other Name(s): GW 610742
- CAS: 317318-84-6
- Solubility: DMSO, Ethanol, PEG
- Molar Mass: 471.488 g/mol
- Chemical Formula: C21H17F4NO3S2
- Melting Point: 134.5-135.5°C
- Appearance: Off-white fine powder
- Biological half-life: No Data Available
- Research: 5-20mg
Description
GW 0742 is a selective peroxisome proliferator-activated receptor (PPAR)-δ agonist. GW 0742 shows great potential for treating metabolic syndrome, cardiovascular disease, inflammation, diabetes and obesity, even in hosts fed on a high fat diet. GW 0742 can increase serum HDL cholesterol (good cholesterol), increase fatty acid breakdown in skeletal muscle, improve insulin resistance and inhibit inflammation. GW 0742 has the ability to improve glucose homeostasis in diabetic hosts through activation of PPAR-δ.
What is the PPARδ receptor: exercise can increase (PPARδ) expression in skeletal muscle; PPARδ regulates cellular metabolic functions that regulate energy balance, fatty acid uptake, and insulin secretion and sensitivity – basically it reprograms muscle fibers to enhance endurance and shred fat.
During trials, GW 0742 showed metabolic changes of peripheral lymphoid tissues by increasing the fatty acid oxidation gene expression during exercise. It also decreased visceral adipose tissue mass and skeletal muscle inflammation, increased endurance and increased insulin sensitivity. This means that GW 0742 provide a therapeutic approach targeting the PPARβ/δ pathway to improve obesity treatment.
GW 0742 exhibits 1,000-fold selectivity over the other human PPAR subtypes.
Reviews
There are no reviews yet.